Skip to content

Effects of varenicline and cognitive bias modification on responses to smoking cues

Effects of varenicline and cognitive bias modification on neural response to smoking-related cues

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN65690030
Enrollment
72
Registered
2014-01-30
Start date
2012-07-23
Completion date
Unknown
Last updated
2019-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Smoking cessation Mental and Behavioural Disorders Mental and behavioural disorders due to use of tobacco

Interventions

Participants are randomised to the training group or the drug group Drug group: Participants would receive either varenicline or placebo in tablet form. Varenicline wo

Sponsors

University of Bristol (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Smokes > 10 manufactured cigarettes or > 15 roll up cigarettes per day 2. Smokes within one hour of waking 3. Aged between 18 and 40 years 4. Able to attend all of the study session 5. English as first language or equivalent level of fluency

Exclusion criteria

Exclusion criteria: 1. Female volunteers who are pregnant or breast feeding 2. Female volunteers not using adequate contraception 3. Volunteers who do not currently have a GP 4. Current or previous substance or alcohol misuse or dependence [other than nicotine] 5. Alcohol use in excess of 35 Units/week if female or 50 Units/week if male 6. Caffeine use = 8 cups per day 7. Significant current or past psychiatric illness (Axis 1 or 2 psychiatric diagnoses) as diagnosed by a psychiatrist 8. Clinically significant abnormality including cardiology risk factors and history of arrhythmia (as assessed by self-report) 9. Ongoing use of medication (i.e. intake of any medication within 8 weeks of study, with exception of local treatment and occasional paracetamol or non-steroidal anti-inflammatory drugs, e.g., aspirin or ibuprofen) 10. Smokers actively trying to give up smoking during the study period 11. Uncorrected visual impairment (including colour-blindness) 12. Uncorrected auditory impairment 13. Condition that makes MRI scanning unsafe (e.g. metallic implants; history of metal-working) 14. Unable to tolerate scanning environment (as established during a short anatomical MRI scan on day 0) 15. Hypersensitivity to Champix

Design outcomes

Primary

MeasureTime frame
1. Neural responses to smoking-related cues 2. Cognitive bias

Secondary

MeasureTime frame
1. Questionnaire of Smoking Urges 2. Minnesota Nicotine Withdrawal Scale (MNWS)

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 19, 2026